問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital

Division of General Internal Medicine

Division of Rheumatology

更新時間：2023-09-19

鄭喬峰
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鄭喬峰

List

10Cases

2025-06-01 - 2029-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-06-16 - 2026-07-31

Phase III

Active
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel- group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

  • Condition/Disease

    moderate-to-severe systemic lupus erythematosus (SLE)

  • Test Drug

    tablet

Participate Sites
11Sites

Not yet recruiting1Sites

Recruiting10Sites

2023-12-26 - 2026-05-14

Phase III

Active
xxxxxx

  • Condition/Disease

    xxxxxx

  • Test Drug

    xxxxxx

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2024-07-01 - 2027-01-31

Phase II

Active
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    injection

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2024-07-17 - 2027-07-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-05-31 - 2027-09-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-12-01 - 2030-03-19

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-12-02 - 2030-12-09

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2024-12-02 - 2030-12-09

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-05-31 - 2027-09-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB